Global Rheumatoid Arthritis Drugs/Therapeutics Market 2021-2027

Rheumatoid Arthritis is a chronic inflammatory disorder which affects the immune system and causes joint pain which includes hands, feet, knees, elbows, and swelling of joints. The immune system of the human body targets its own tissue, including joints. Internal organs are attacked in extreme cases. The linings of joints are affected by rheumatoid arthritis, which causes painful swelling. The inflammation associated with rheumatoid arthritis can lead to bone degradation and joint deformities over time. RA medicines and drugs can help reduce the disease’s course. Anti-rheumatic medicines are a family of pharmaceuticals that can be used to treat most instances (DMARDS).

According to a market report published by Bizwit Research & Consulting, LLP, the Global Rheumatoid Arthritis Drugs/Therapeutics Market is valued at approximately USD  24554.3 Million in 2020 and is anticipated to grow with a healthy growth rate of nearly  4.52%% over the forecast period 2021-2027.

Biosimilars are drug products whose efficacy and safety have been proved to be equal to previous biological products in both experimental and clinical settings, and whose costs are lower than those of the preceding medications. Biosimilars for the treatment of RA are now being developed around the world, thereby driving the growth of the Global Market during the forecasted period. According to Arthritis Organization, Biologics and biosimilars are special types of disease-modifying antirheumatic drugs (DMARD). They are usually recommended when other DMARDs have failed to function. Many persons with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and other types of autoimmune, inflammatory arthritis benefit from these effective medications.

With the increase in preference towards biologics and biosimilars, owing to the benefits it offers, such as, cost-effectiveness, enhanced patient accessibility, etc. the industry is also witnessing several product launches as well as FDA approvals for biologics or biosimilars for the treatment of rheumatoid arthritis. For instance, In August 2017, Boehringer Ingelheim Pharmaceuticals, Inc. announced that Cyltezo, a biosimilar to Humira has been approved by the FDA for the treatment of multiple chronic inflammatory diseases including rheumatoid arthritis. In October 2018, Amgen has announced the launch of AMGEVITATM, a biosimilar of adalimumab, which has been approved by the FDA to treat moderate to severe rheumatoid arthritis.

Global Rheumatoid Arthritis Drugs/Therapeutics Market Size study, by Molecule type (Biopharmaceutical and pharmaceutical) by sales channel (Prescription and Over the Counter (OTC)) and Regional Forecasts 2021-2027

The total market revenue is calculated on the basis of revenue generated through the sales of Rheumatoid Arthritis Drugs/Therapeutics. Major companies covered under the report include Abb Vie, Amgen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., UCB S.A.

Review the reports at
Data drives better decisions
Bizwit Research & Consulting LLP